Formulary Watch |

All News - Page 2

 Alex Puhovoy-stock.adobe.come
IQVIA: Medicine Spending Expected to Grow 4% to 7% by 2028
IQVIA: Medicine Spending Expected to Grow 4% to 7% by 2028
May 7, 2024
Over the next five years, list prices of protected prescription drugs are expected grow between 1% and 4% a year, while net prices are expected to decline by the same amount, IQVIA predicts.
FDA Assigns Action Date for Subcutaneous Opdivo
FDA Assigns Action Date for Subcutaneous Opdivo
FDA Assigns Action Date for Subcutaneous Opdivo
May 6, 2024
Bristol Myers Squibb is seeking approval of the subcutaneous formulation for all previous indications of Opdivo. The FDA has assigned a goal date of Dec. 29, 2024.
Survey: Managing Total of Cost of Care is Top Priority
Survey: Managing Total of Cost of Care is Top Priority
Survey: Managing Total of Cost of Care is Top Priority
May 3, 2024
Specialty medications represent a large and growing proportion of overall drug spend, but plans and employers are struggling to understand their costs to make good decisions, finds the latest PSG Specialty Drug report.
agenturfotografin-stock.adobe.com
Alvotech to Manufacture Interchangeable Humira Biosimilar for Teva and Quallent
Alvotech to Manufacture Interchangeable Humira Biosimilar for Teva and Quallent
May 1, 2024
The high-concentration biosimilar will be distributed under Quallent’s private label and will be available in June through Evernorth’s Accredo specialty pharmacy.
Express Scripts Adds Zymfentra to National Preferred Formulary
Express Scripts Adds Zymfentra to National Preferred Formulary
Express Scripts Adds Zymfentra to National Preferred Formulary
April 29, 2024
Zymfentra launched in March 2024 as the first subcutaneous formulation of infliximab for patients with ulcerative colitis and Crohn’s disease. It has a list price of $6,181.08 for two shots over four weeks.
 Сергей Шиманович-stock.adobe.com
FDA Approves Xolremdi for Ultra Rare Immune Disorder
FDA Approves Xolremdi for Ultra Rare Immune Disorder
April 29, 2024
Xolremdi is the first therapy for WHIM syndrome, which can cause recurrent lung infections and papillomavirus-related warts. It’s available in two doses: 400 mg for an annual cost of $496,400 and 300 mg for an annual cost of $372,300.
Елена Бутусова-stock.adobe.com
FDA Approves Pfizer’s Gene Therapy Beqvez for Hemophilia
FDA Approves Pfizer’s Gene Therapy Beqvez for Hemophilia
April 26, 2024
Beqvez (fidanacogene elaparvovec) is priced at $3.5 million, which is on parity with Hemgenix, the first one-time therapy to treat adults with hemophilia B. Pfizer’s warranty will refund insurers and continue to provide coverage for patients if they change insurers.
FDA Approves Ojemda for Children with Brain Tumors
FDA Approves Ojemda for Children with Brain Tumors
FDA Approves Ojemda for Children with Brain Tumors
April 25, 2024
Ojemda will have a wholesale acquisition cost of $33,916 for a 28 day supply and will be distributed through specialty pharmacies Biologics by McKesson and Onco360.
Vink Fan-stock.adobe.com
 No Silver Bullet for Paying for Gene Therapies
No Silver Bullet for Paying for Gene Therapies
April 24, 2024
New White Paper looks at the solutions and policy options of how to pay for high-cost gene therapies when there is still so much uncertainty about the outcomes and the durability of clinical benefits.
FDA Approves Bladder Cancer Immunotherapy
FDA Approves Bladder Cancer Immunotherapy
FDA Approves Bladder Cancer Immunotherapy
April 23, 2024
ImmunityBio’s Anktiva is an antibody cytokine fusion protein approved to treat patients with non-muscle invasive bladder cancer.
FDA Approves Pen Form of Entyvio for Crohn’s Disease
FDA Approves Pen Form of Entyvio for Crohn’s Disease
FDA Approves Pen Form of Entyvio for Crohn’s Disease
April 19, 2024
Entyvio as an injection and subcutaneous formulations is approved to treat both Crohn’s and ulcerative colitis.
FDA Approves Stelara Biosimilar, Selarsdi
FDA Approves Stelara Biosimilar, Selarsdi
April 18, 2024
Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
FDA Approves GSK's BLA for 5-in-1 Meningococcal Vaccine
FDA Approves GSK's BLA for 5-in-1 Meningococcal Vaccine
April 17, 2024
The vaccine combines the antigenic components of its two meningococcal vaccines: Bexsero and Menveo. The action date is Feb. 14, 2025.
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
April 12, 2024
Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.
 jolygon-stock.adobe.com
Drugs to Watch: Mental Health Conditions
Drugs to Watch: Mental Health Conditions
April 11, 2024
The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
© 2024 MJH Life Sciences

All rights reserved.